UChicago 6th Annual Updates from ASH 2020: Practice Changing Abstracts
ASH Highlights on High-Risk MDS in HMA Era: Oral HMAs, BCL2 Inhibition, Macrophage Checkpoint Inhibition, TP53 Modulators
Login to view comments.
Click here to Login